Early Waning of Maternal Measles and Meningitis C Antibodies
NCT ID: NCT02219061
Last Updated: 2014-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2014-05-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Geometric mean titers(GMTs) of measles and meningitis C.
* Follow-up on 0 month, 3rd month,5th month and 7th month after birth.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children
NCT01255124
Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong
NCT02443233
Evaluation of Immunoprotection Provided by Hepatitis B Vaccine After Birth in Healthy Children
NCT04439435
A Study of the Interruption on the Mother-to-child Transmission of Hepatitis B Virus （HBV MTCT）in Newborns at High Risk
NCT02901418
Observational Study on Pregnant Women With Chronic Hepatitis B and Their Infants
NCT03539016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Maternal antibodies are supposed to wane after birth. Serums of the placenta(0 month), children of 3 months, 5 months and 7 months old will be collected and the geometric mean titers (GMTs) of measles and meningitis C will be confirmed by using the ELISA test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GMT
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
7 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Center for Disease Control and Prevention
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ming Wang
Role: PRINCIPAL_INVESTIGATOR
Guangzhou CDC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou Center for Disease Control and Prevention
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chuanxi
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GZCDC001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.